20 August 2026

Merck and Moderna report positive Phase 3 cancer vaccine results

• Merck and Moderna tested a personalized mRNA cancer vaccine that uses AI to analyze each patient's tumor DNA and design a custom treatment.
• The vaccine identifies neoantigens, which are tumor-specific proteins that can trigger the immune system to attack cancer cells.
• Phase 3 trials, the final major testing stage before regulatory approval, showed positive results for this approach combined with Merck's existing drug KEYTRUDA.

How it was covered

The NeuronPete Huang & Grant Harvey

Merck and Moderna announced positive Phase 3 results for an individualized mRNA cancer therapy where AI algorithms analyze patient tumor sequencing data to predict neoantigens that trigger immune response, then encode them into custom mRNA therapy paired with KEYTRUDA. The newsletter frames this as a major milestone showing AI's real-world medical impact.